Ranbaxy Reports Quarterly Loss Ahead of Sun Pharma Acquisition

Ranbaxy Laboratories Ltd. (RBXY), which is in the process of being acquired by Sun Pharmaceutical Industries Ltd. (SUNP), posted a quarterly loss after finance costs rose and the U.S. banned its Punjab factory.

The company reported a loss of 736.5 million rupees ($12.3 million) in the three months ended March compared with a profit of 1.26 billion rupees a year earlier, the Gurgaon-based company said in a statement to the stock exchange today.

With import bans on four of its Indian facilities and increased regulatory compliance costs, Ranbaxy’s challenge is to raise profitability which lags behind rivals including Dr. Reddy’s Laboratories Ltd. If the acquisition is approved, Ranbaxy would need to resolve production problems to bolster its new owner’s pipeline of drugs.

Ranbaxy’s chief bulk ingredient manufacturing facility in Toansa, Punjab was banned from supplying to the U.S. in January, after a week-long FDA inspection earlier in the month found manufacturing lapses.

A unit of Japan’s Daiichi Sankyo Co., Ranbaxy’s products include a generic version of Pfizer Inc.’s cholesterol-lowering drug Lipitor.

To contact the reporter on this story: Ketaki Gokhale in Mumbai at kgokhale@bloomberg.net

To contact the editors responsible for this story: Anjali Cordeiro at acordeiro2@bloomberg.net Subramaniam Sharma

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.